WHAT IS IMMUNOTHERAPY?
- İmmünoterapi, bağışıklık sistemini güçlendirerek kanser hücrelerini yok etmeyi hedefleyen ve özellikle metastatik ürotelyal karsinom ile yüksek riskli hastalar için kritik bir tedavi yöntemidir.
- 2026 EAU Kılavuzlarına göre tedavi kararları; hastanın evresi, biyobelirteç profili ve genel sağlık durumu göz önünde bulundurularak multidisipliner bir yaklaşımla kişiselleştirilmelidir.
- Nivolumab ve Pembrolizumab gibi ilaçlarla damardan uygulanan bu tedavi, kemoterapiden farklı mekanizmalarla çalışır ve bağışıklık sistemi kaynaklı yan etkilerin takibini gerektirir.
İçerik yapay zeka ile optimize edilmiştir
Immunotherapy in Bladder Cancer Treatment
Immunotherapy is a modern cancer treatment that helps the body's immune system recognize and destroy cancer cells more effectively. It has become an essential treatment option for selected patients with Muscle-Invasive Bladder Cancer (MIBC) and metastatic urothelial carcinoma. According to the 2026 European Association of Urology (EAU) Guidelines, immunotherapy plays a critical role as adjuvant treatment after radical cystectomy, in metastatic disease, and as part of systemic therapy in selected clinical situations.
How Does the Immune System Fight Cancer?
Under normal conditions, the immune system can identify and eliminate abnormal cells. However, cancer cells may develop mechanisms that allow them to escape immune surveillance. Immune checkpoint inhibitors help restore the immune system's ability to recognize and destroy these cancer cells, effectively re-activating the body's natural defenses.
What is Immunotherapy?
Immunotherapy is a systemic cancer treatment that strengthens the body's immune system to recognize and attack cancer cells. Unlike chemotherapy, which directly targets rapidly dividing cells (both healthy and cancerous), immunotherapy enhances the body's natural immune defenses specifically against the malignancy.
Who May Benefit from Immunotherapy?
According to the 2026 EAU Guidelines, immunotherapy may be considered for the following patient groups:
- Selected patients with high-risk disease following radical cystectomy.
- Patients with metastatic urothelial carcinoma.
- Selected cisplatin-ineligible patients.
- Other approved clinical indications according to current international guidelines.
Treatment decisions should always be made by a multidisciplinary team to ensure the most accurate approach for the individual patient.
Medications and Administration
Which Medications are Used?
The most commonly used immune checkpoint inhibitors for bladder cancer include:
| Medication | Type of Treatment |
|---|---|
| Nivolumab | Immune Checkpoint Inhibitor |
| Pembrolizumab | Immune Checkpoint Inhibitor |
| Atezolizumab | Immune Checkpoint Inhibitor |
| Avelumab | Immune Checkpoint Inhibitor |
The most appropriate medication depends on the patient's disease stage, previous treatments, biomarker profile, and overall clinical condition.
How is Immunotherapy Administered?
Immunotherapy is generally administered intravenously at regular intervals. The total treatment duration depends on the disease stage, treatment response, observed side effects, and current clinical recommendations.
Possible Side Effects
Because immunotherapy activates the immune system, it may cause immune-related side effects. Most immune-related adverse events can be successfully managed when recognized and treated promptly. Common side effects include:
- Skin rash
- Thyroid dysfunction
- Colitis
- Pneumonitis
- Elevated liver enzymes
The EAU 2026 Key Message for Patients
It is important to note that immunotherapy is not appropriate for every patient with bladder cancer. Treatment decisions must be individualized according to tumor characteristics, previous treatments, overall health, biomarker status, and a comprehensive multidisciplinary evaluation.
Multidisciplinary Treatment Planning with Assoc. Prof. Dr. Serdar Yalçın
Assoc. Prof. Dr. Serdar Yalçın evaluates patients with bladder cancer in Bodrum, Türkiye, collaborating with specialists in medical oncology, radiology, pathology, and other relevant disciplines. Immunotherapy, chemotherapy, robotic surgery, and other treatment options are carefully individualized according to the latest EAU Guidelines.
In addition to patients from Bodrum and the Muğla region, individuals from across Türkiye and abroad seek consultation for second opinions and personalized bladder cancer treatment planning. Patients frequently emphasize the importance of:
- Detailed communication and evidence-based recommendations.
- Multidisciplinary decision-making.
- Individualized care and comprehensive support throughout the treatment process.
Conclusion
Immunotherapy represents one of the most significant advances in modern bladder cancer treatment. In appropriately selected patients, it may provide durable disease control and has become a cornerstone of contemporary international treatment guidelines.
Frequently Asked Questions
-
Is immunotherapy the same as chemotherapy?
No. Immunotherapy and chemotherapy work through completely different mechanisms; while chemotherapy attacks cells directly, immunotherapy empowers the immune system. -
Can every patient with bladder cancer receive immunotherapy?
No. Eligibility depends on disease stage, previous treatments, overall health, approved indications, and other individual clinical factors. -
Does immunotherapy cause hair loss?
Significant hair loss is uncommon with immune checkpoint inhibitors and is much less frequent than with conventional chemotherapy.
